Tsumura & Co (Tsumura) manufactures and commercializes pharmaceuticals derived from crude drugs sourced from plants and other natural products. The company holds over 80% of the domestic prescription Kampo formulation market. Tsumura operates in the pharmaceutical industry, focusing on Kampo medicines and traditional Chinese medicines, with a significant presence in both the domestic market and China.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The R&D activities of the company focus on the development of new products and new technologies both in Japan and overseas. The company also focuses on the research of cultivation technology to secure stable supplies of raw material crude drugs, enhancing the quality of raw material crude drugs and improving Kampo product quality control and manufacturing technology. The company planning to introduce upland ginseng cultivation and increase the clinical facilities in the US. It operates a central research laboratory in Ibaraki, Japan. The R&D units of Tsumura are Tsumura Kampo Research Laboratories which is engaged in basic and clinical research to advance the standardization of Kampo treatment, focusing on areas such as geriatric health, cancer, women's health, and cardiovascular health; Tsumura Advanced Technology Research Laboratories which is focused on research and development using KAMPOmics, including pre-symptomatic disease R&D, personalized medicine R&D, systems biology research, and Kampo data science; and CMC Development Research Laboratories which is responsible for the improvement and development of manufacturing technology and quality control technology, including formulation research, quality research, and quality assurance. Tsumura holds patents related to new analysis technologies used in quality testing and quality control for exogenous impurities, with specific patents for analysis methods related to agrochemical residue in Japan, the United States, and China. In FY2025, the company reported research and development expenses of JPY8,355 million which amounted to 4.6% of the company’s total revenue and grew 0.8% YoY.